Food and Drug Administration Approves Eli Lilly Weight Loss Pill

What Happened?

Yesterday, the U.S. Food and Drug Administration (FDA) approved Eli Lilly’s orforglipron pill for weight loss in the United States. The oral glucagon-like peptide-1 (GLP-1) will be branded under the name foundayo. Lilly expects to launch the drug on its direct-to-consumer channel by April 6th, 2026, with retail pharmacy and telehealth provider’s gaining access shortly afterwards.

According to the FDA, their decision was based on results from recent clinical studies, which demonstrated that patients taking the highest dose of foundayo and who remained on treatment lost an average of 12.4% of their body weight.

Why it Matters

GLP-1 weight loss drugs have become prevalent in the United States, with as many as one in eight Americans taking those types of drugs in 2025. Despite the widespread use, the numbers are lower than they could be because many patients dislike needles, and most GLP-1 drugs have been available only via injection until recently. Three months ago, the FDA approved Novo Nordisk’s GLP-1 weight loss drug in pill form, and now Eli Lilly also has a GLP-1 drug that can be taken as a pill.

Unlocking $2.1 Trillion Potential

One company has developed a technology that extracts valuable resources from coal without burning it. From hydrogen to diesel, fertilizer, and more, Frontieras has the potential to address $2.1T worth of markets.

It’s similar to when John D. Rockefeller commercialized oil refining technology. If Frontieras captures just 2% of the global coal market, they have a roadmap to achieve a $1T valuation.

They just completed the land purchase for their $850M flagship facility. Now, with their NASDAQ ticker (FASF) reserved and the White House favoring domestic energy, this company is positioned for potential valuation impact.* Become a Frontieras shareholder before their share price changes on April 9.

Eli Lilly CEO David Ricks issued a statement saying, ‘Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one.’ The FDA approval of oral GLP-1 weight loss drugs like foundayo will likely mean even more people will take those types of drugs in 2026 than they did in 2025. For patients who are already on the medication, many will likely switch to the pill form because it is easier to swallow a pill than to receive injections. 

GLP-1 medications mimic a natural gut hormone that regulates appetite and blood sugar. They work by stimulating insulin release, reducing sugar production in the liver, slowing stomach emptying to increase fullness, and acting on brain centers to reduce hunger and cravings, leading to reduced calorie intake and weight loss. People who take GLP-1s eat less because they don’t feel hungry as often, and over time, the decreased calorie intake leads to weight loss. 

Patients taking GLP-1 drugs for one year or longer report an average weight loss of fifteen to twenty percent of their total body weight. The success of GLP-1s has revolutionized weight loss treatments, especially in countries like the United States, where an estimated fifty percent of the adult population can be classified as obese or overweight. GLP-1 drugs do have side effects such as nausea and muscle loss, but on average, the effects tend to be mild.

How it Affects You

Patient demand for GLP-1s in pill form is likely to increase in 2026, and manufacturers may not be able to keep up. If there are shortages, compounding pharmacies may be authorized to produce generic versions, though compounded versions typically do not receive the same amount of testing or evaluation as the original formulas. In either case, pill versions of GLP-1s will accelerate their usage in the U.S., which is the single biggest market for the drugs.

*Disclaimer: This is a paid advertisement for Frontieras’s Regulation A offering. Please read the offering circular at https://invest.frontieras.com/ 

Reservation of the ticker symbol is not a guarantee that we will be listed on the NASDAQ. Listing on the NASDAQ is subject to approvals.

Under Regulation A+, a company has the ability to change its share price by up to 20%, without requalifying the offering with the SEC.